Tuberculous meningitis (TBM) is a devastating form of tuberculosis that occurs predominantly in children and in immunocompromised adults. To study the pathogenesis of TBM, a rabbit model of acute mycobacterial central nervous system infection was set up (8-day study). Inoculation of live Mycobacterium bovis Ravenel intracisternally induced leukocytosis (predominantly mononuclear cells), high protein levels, and release of tumor necrosis factor-a (TNF-a) into the cerebrospinal fluid within 1 day. Histologically, severe meningitis with thickening of the leptomeninges, prominent vasculitis, and encephalitis was apparent, and mortality was 75% by day 8. In animals treated with antituberculous antibiotics only, the inflammation and lesions of the brain persisted despite a decrease in mycobacteria; 50% of the rabbits died. When thalidomide treatment was combined with antibiotics, there was a marked reduction in TNF-a levels, leukocytosis, and brain pathology. With this combination treatment, 100% of the infected rabbits survived, suggesting a potential clinical use for thalidomide in TBM.
Tuberculous meningitis (TBM) is the most devastating comcerebrospinal fluid (CSF) leukocytosis, increased protein influx, and lactate accumulation [14 -16] . In humans with bacteplication of Mycobacterium tuberculosis infection in humans. It is predominantly a disease of children in the developing rial meningitis, CSF levels of TNF-a and IL-1b correlate with the severity of disease and clinical outcome [17, 18] . This world and of the elderly or immunocompromised in the United States [1, 2] . The mortality rate of TBM is Ç50%, and most inflammatory process ultimately leads to brain edema, vascular infarcts, necrosis, and irreversible brain damage. Hence, control of the survivors of this infection suffer permanent neurologic sequelae [1, 3] . The underlying mechanisms that determine the of inflammation even during antibiotic treatment of CNS infections is of vital importance. development of the immune response and clinical manifestations of TBM are poorly understood. Insights into its pathoWe describe here a rabbit model of acute mycobacterial infection in the CNS, which resembles human TBM immunophysiology still rest on anatomic and histologic descriptions of 50 or 60 years ago [4 -6] .
logically, clinically, and pathologically. We used this model to study the inflammatory cascade of mycobacterial CNS infecIt has long been known that infections in the central nervous system (CNS) are extremely dangerous because of the inflamtion and then intervened with a combination of antimycobacterial drugs and thalidomide (a-N-phthalimidoglutarimide), a mation resulting from the mobilization of the host defense. Macrophages exposed to invading mycobacteria or their proddrug recently shown to inhibit production of TNF-a [11, 19 -23] . The effects of this combination therapy on brain pathology ucts release proinflammatory cytokines such as interleukin1b (IL-1b) and tumor necrosis factor-a (TNF-a) [7 -11] .
and on survival of mycobacteria-infected rabbits were evaluated. TNF-a plays a definitive role in granuloma formation and the containment of mycobacterial infection [12, 13] . However, in addition to the protective role of TNF-a, it has been shown Materials and Methods that the local production of inflammatory cytokines (including TNF-a) in the brain in response to experimental bacterial menInfecting organism. Mycobacterium bovis Ravenel (Trudeau ingitis leads to altered blood-brain barrier (BBB) permeability, Mycobacterial Culture Collection, TMC no. 401), known to be highly virulent for rabbits, was selected for this study. Mycobacteria were grown initially in Middlebrook 7H9 broth (Difco Laboratories, Detroit) for Ç2 weeks and then cultured in Proskauer and the animals were anesthetized with a combination of ketamine (0. 5 Antituberculosis therapy. Isoniazid (Nydrazid Injection, Apothecon; Bristol-Myers Squibb, Princeton, NJ) was administered at mL/kg) and xylazine (3.5 mL/kg) administered intramuscularly. a dose of 30 mg/day as an intramuscular injection. Rifampicin The rabbits were then placed in a stereotaxic frame. A spinal (Rifadin; Merrell Dow Pharmaceuticals, Kansas City, MO) was needle was introduced into the cisterna magna, and 0.3 mL of CSF administered at a dose of 30 mg/day in a suspension of saline via was withdrawn. Next, 0.12 mL of live mycobacteria was injected a rubber intragastric tube. Thus, the dose of the antibiotics was intracisternally. For each experiment, 4-6 animals were infected.
Ç15 mg/kg per day, which is the standard human antimycobacteControl animals were injected intracisternally with 0.12 mL of rial treatment dosage. pyrogen-free saline. In some of the experiments, CSF samples Data. Results are presented as the means of values obtained were withdrawn at 0, 2, 4, 6, and 24 h after inoculation. In other for all animals evaluated at each time point. SDs are shown for experiments, meningitis was allowed to progress for 8 days, and all data points unless the number of animals remaining for evaluathe samples were obtained every 24 h. After infection, animals tion was õ3. Data were analyzed using an independent t test to were housed separately, each in an individual cage. During the compare controls with treated animals. For the survival data, the experiments, rabbits were rehydrated daily with 60 mL of pyrogenKaplan-Meier survival analysis was used. P õ .05 was considered free saline subcutaneously. At the end of each experiment, rabbits significant. Extreme outlying values for TNF-a levels and CSF were euthanatized by an overdose of pentobarbital. The brains leukocyte counts were found to be indicators of imminent death were removed and fixed in 10% buffered formalin (vol/vol) (Fisher of the animals. Thus, when an individual value for TNF-a or Chemical, Fairlawn, NJ).
leukocyte number was ú3-fold higher than the mean, that value CSF. Immediately after collection, 100 mL of CSF was rewas not used in the calculation of the SD. moved for determination of the bacterial load. Ten-fold serial dilutions were plated onto Middlebrook 7H10 agar (Difco). Plates were incubated at 37ЊC for 2-3 weeks. Organisms were counted
Results
as colony-forming units (cfu). The remainder of the CSF was centrifuged at 10,000 g for 5 min, and the supernatant was stored 
1A). Examination of cytospin preparations of the CSF showed
IL-1a and IL-1b assays. Both cytokines were assayed in CSF that the acid-fast bacilli were usually associated with mononusupernatants as described by the manufacturer, using commercial clear phagocytes that had entered into the subarachnoid space RIA kits designed for the rabbit (Cytokine Sciences, Boston).
(not shown). Leukocyte accumulation in the CSF increased Duplicate 100-mL CSF samples were assayed per tube. The minifrom saline control levels of £300 cells/mL to §1000 cells/ mal detection level of IL-1b was 30 pg/mL and of IL-1a was 40 pg/mL.
mL by day 1 after mycobacterial infection, indicating that the in CSF of infected rabbits (n Å 10). C, Protein levels (mg/mL) in CSF of infected rabbits (n Å 8). D, Tumor necrosis factor-a (TNF-a) concentration (U/mL) in CSF (ᮀ) and in plasma (᭝) of infected rabbits (n Å 10). Nos. in parentheses pertain to no. of animals included in each study group at start of study. All values are means { SD for no. of animals studied at each time point. Following death of animals, if n õ3, SD was not included.
increase during the period of observation (figure 1C). In addiarachnoid space with large numbers of inflammatory cells, which consisted primarily of mononuclear cells (macrophages tion to protein accumulation in the CSF, cytokines were also induced. TNF-a in the CSF, which at baseline is 0, peaked 2 and lymphocytes) and fewer polymorphonuclear leukocytes (figure 2B). Vasculitis of blood vessels within the meninges h after mycobacterial inoculation and was maintained at measurable levels throughout the experiment ( figure 1D ). Secondwas frequently observed and was characterized by infiltration of the adventitia ( figure 2C ). This process progressed in the ary peaks of TNF-a preceded the death of infected animals. In the plasma of the rabbits, TNF-a was detected 1 day after later stages of infection (by 7 days) to extension of the inflammation transmurally with fibrinoid necrosis of the smooth musthe infection and remained elevated throughout the experiment ( figure 1D ). Low levels of IL-1b (199 { 102 pg/mL at 2 h) cle of the vessel walls ( figure 2D ). In some cases, there was also extension of the inflammation to the deeper perivascular and IL-1a (173 { 111 pg/mL at 2 h) were detected in CSF of infected animals (data not shown).
areas within the neuropil (encephalitis) (figure 2E). Acid-fast staining of sections of tissue sampled 4-8 days The inflammatory process described above correlated with the clinical course of experimental mycobacterial meningitis.
after infection showed abundant intracytoplasmic bacilli within macrophages in the meninges as well as perivascularly in the All infected rabbits showed severe clinical signs, including somnolence or irritability, loss of coordination, lateral recumneuropil. In addition, scattered acid-fast bacilli were seen in the macrophages within histologic sections of the lung and spleen, bency, ophthalmitis, hemiparesis, or hemiplegia. Infected animals survived 2 -8 days after intracisternal inoculation of myand viable bacilli could be cultured from these organs (not shown). The presence of viable bacilli in organs other than the cobacteria (see below).
Histopathologic examination of brains of rabbits infected CNS indicated that once the BBB was breached, mycobacteriainfected cells probably crossed back from the subarachnoid space with M. bovis Ravenel demonstrated a granulomatous meningitis, which progressed in severity over time. By 24 h, there was into the blood. The systemic infection may have contributed to the presence of TNF-a in the plasma ( figure 1D ). marked thickening of the leptomeninges and distension of the Effect of thalidomide on CSF cytokine levels and survival of rabbits. The immunomodulatory drug thalidomide has been previously shown to reduce TNF-a production in vitro and in vivo in rodents [26 -29] . To determine whether such immunomodulation would affect the pathophysiology of CNS mycobacterial infection, experimentally infected rabbits were treated with thalidomide. Infected rabbits received either 100 or 200 mg/day of thalidomide orally (by gavage) starting 24 h before infection. A group of untreated, infected animals served as controls. Thalidomide treatment was continued for 6 days. Animals were monitored for 8 days after infection.
Administration of 200 mg/day thalidomide to rabbits resulted in plasma drug levels ranging from 10 -20 mg/mL at 2 h to 20-25 mg/mL at the 8-h drug delivery. By 24 h (the time of the next dose delivery), plasma levels of thalidomide had dropped to õ0.2 mg/mL. CSF drug levels reached 10 -13 mg/ mL by 2 h after delivery of thalidomide. Treatment of rabbits with this dose of thalidomide (200 mg/day) significantly (P Å .01) reduced peak TNF-a levels in the CSF ( figure 3A) . Similar inhibition was observed in the plasma, where TNF-a concentrations were reduced in a dose-dependent manner ( figure 3B ). Furthermore, a delay in TNF-a production was seen in animals treated with 200 mg/day thalidomide. Administration of a lower dose (100 mg/day) of thalidomide did not result in significant changes in peak CSF TNF-a levels at 2 h after infection nor were plasma TNF-a levels fully reduced compared with controls ( figure 3A, B) . In control animals, TNF-a was detected in the plasma by 1 day after infection, whereas in rabbits treated with thalidomide at either 100 or 200 mg/day, TNF-a was detected in the plasma only on day 2.
Thalidomide treatment was associated with prolonged survival of the infected rabbits ( figure 3C ). However, when thalidomide treatment was discontinued at day 6, the rabbits became moribund, and by day 8 after infection, no significant residual effect on mL) in CSF. Significant reduction in TNF-a levels was observed at 2 bovis -infected rabbit 24 h after infection, demonstrating marked h in response to 200 mg/day thalidomide (t test, P Å .01). B, TNF-a thickening of leptomeninges (arrows) and distension of arachnoid levels (U/mL) in plasma. Reduction in TNF-a levels was statistically space by large nos. of inflammatory cells. Vessels within neuropil significant on day 4 in response to 200 mg/day thalidomide (t test, P Å are surrounded by leukocytes (arrowheads) (hematoxylin-eosin; pho-.05). C, Survival (% alive at each time point) of rabbits. Significant tographed at 125). C, Perivascular inflammatory infiltration of adveneffect on survival of rabbits was observed on day 6 of thalidomide titia within meninges 48 h after infection (arrow) (hematoxylin-eosin; treatment (Kaplan-Meier analysis, P Å .017). Values for A and B are photographed at 1100). D, Progressive, severe meningitis 7 days means { SD for group. SD not shown when n õ3. after infection, with necrotizing vasculitis of a meningeal vessel and extension of inflammation transmurally (arrow). Note fibrinoid survival of the infected rabbits was observed. Thus, thalidomide necrosis (nec) of smooth muscle of vessel wall (hematoxylin-eosin; protected rabbits from death only during the time infected animals photographed at 1100). E, Infected rabbit 7 days after infection with were receiving the drug. A side effect of thalidomide treatment extension of perivascular inflammation to neuropil (arrowhead) (hematoxylin-eosin; photographed at 1100).
was sedation, which was dose-dependent.
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04-23-98 20:33:27 jinfal UC: J Infect extension into the deeper perivascular areas of the neuropil (figure 5C). Treatment with antibiotics alone did not significantly alter the morphologic severity of the meningitis (figure 5B), although the inflammation appeared to occur more focally relative to the control infected animals. Some acid-fast organisms could still be demonstrated within phagocytic cells in the meninges in response to antibiotic therapy with or without thalidomide but in decreased numbers compared with the untreated, infected animals.
To measure the efficacy of antituberculous treatment, mycobacteria were cultured from the CSF and quantitated by the cfu assay. By day 2 after the infection and initiation of antituberculous treatment, significant reductions in cfu were observed in the antibiotic-treated animals compared with the cfu in the control group (P õ.04) ( figure 6A ). The addition of thalidomide to the antibiotic treatment did not interfere with bacillary clearance. points (4 -8 days). In rabbits receiving antibiotics combined with thalidomide, TNF-a production in plasma was fully blocked for the first 4 days. In these animals, TNF-a was first Thalidomide treatment in combination with antituberculous therapy. We next evaluated thalidomide as combination therdetected in the plasma 5 days after the infection at reduced levels ( figure 6C ). Leukocyte counts in the CSF of animals apy with antituberculosis treatment in CNS mycobacterial infection. Control animals were infected but not treated. A paraltreated with antibiotics were lower than the levels in the CSF of control untreated rabbits at the later time points (days 6 -8) lel group of rabbits was infected and simultaneously administered 30 mg/day isoniazid intramuscularly and 30 mg/ ( figure 6D ). In animals treated with antibiotics and thalidomide, leukocyte numbers were much lower than in the CSF of either day rifampicin orally. The strain of M. bovis used in the experiments was completely sensitive to these drugs. A third group antibiotic alone or untreated infected rabbits ( figure 6D ). of infected rabbits received 200 mg/day thalidomide by gavage, in addition to the antituberculous drugs. To achieve efficient Discussion CSF concentrations of thalidomide, treatment with this drug was started 24 h before antibiotics. All rabbits were treated
The present study describes a rabbit model of acute mycobacterial meningitis and demonstrates the efficacy of an immuwith the combination of drugs daily for 8 days.
Control infected animals developed acute, rapidly progresnomodulatory approach that improves neurologic outcome and survival. M. bovis infection in rabbits is similar to M. tuberculosive meningitis, and 67% died within a few days (figure 4). Infected rabbits treated with antibiotics had less severe sympsis infection in humans [30] . In human TBM, occlusions of large or small vessels leading to infarcts are the most common toms, and 50% survived until day 8. These data clearly indicate that the antituberculous drugs alone cannot protect the rabbits cause of cranial nerve palsies, hemiparesis, paraplegia, and death [31] . In our animal infection model, we observed all of from death due to mycobacterial meningitis. In contrast, all infected rabbits treated with both antibiotics and thalidomide these neurologic signs following mycobacterial infection of the CNS. Intracisternal inoculation of high doses of M. bovis survived until the end of the observation period with no obvious clinical signs (figure 4). It is of interest to note that in rabbits Ravenel induced a meningitis characterized by release of TNFa and IL-1b, high protein influx, and a massive cellular retreated with antibiotics and thalidomide, interruption of thalidomide treatment after 6 days while maintaining antibiotic thersponse with predominance of mononuclear cells in the CSF. In our model, CSF TNF-a levels correlated with the clinical apy resulted in continued survival of 100% of the animals (not shown).
course of meningitis. The peaks of individual TNF-a levels paralleled the exacerbation of the infection and, in many aniHistopathologic evaluation of the brains showed significant attenuation of the inflammatory response in the combined antimals, preceded death. These observations are analogous to those in clinical studies of bacterial meningitis, in which relabiotic and thalidomide therapy group. In these rabbits, there were only small numbers of inflammatory cells distending the tively higher concentrations of TNF-a in the CSF were associated with more severe disease [15, 17] . subarachnoid space in the meninges, as well as an absence of / 9d46$$ju52
04-23-98 20:33:27 jinfal UC: J Infect The meningitis induced in the experimental model studied which is observed as soon as 2 h after infection (TNF-a peak). Thus, the therapeutic window used here did not mimic that in here is more acute than the naturally occurring infection in humans. Because the infection is so acute and animals start human disease, in which interventions are always initiated after symptoms are manifest. To better mimic human disease, we dying so soon after infection (2 days), intervention with thalidomide had to be started before induction of CNS inflammation, are now developing a more chronic mycobacterial infection / 9d46$$ju52 04-23-98 20:33:27 jinfal UC: J Infect model, which will enable us to initiate treatment with antibiotment reduces the inflammatory response and improves outcome [15] . On the other hand, corticosteroids have been reported to ics and/or thalidomide 10-14 days after infection of the animals.
The inflammatory response in human TBM meningitis is comincrease tuberculous inflammation, leading to massive caseation [37, 38] . In addition, a recent clinical study in children plex and causes much of the damage to the CNS. TNF-a and IL-1b affect vascular endothelium, inducing endarteritis [32] .
with TBM suggests that the use of large doses of prednisone does not have any significant effect on cytokine levels in the Even very small amounts of TNF-a can exert deleterious effects on capillaries already sensitized by exposure to mycobacterial CSF. Other inflammatory parameters also did not show improvement with prednisone treatment [39] . To further compliproducts [33] . The impairment of the vasculature, coupled with edema and hydrodynamic alterations, can lead to a rise in intracate matters, it appears that antituberculous drugs such as rifampicin and ethambutol penetrate the BBB only when the cranial pressure and vascular change. Thus, in addition to bacteriologic cure, the major therapeutic goal in TBM is to obviate the meninges are inflamed, while streptomycin penetrates poorly even into inflamed meninges [1, 40] . Thus, it appears that the vascular impairment induced by inflammatory cytokines and thus prevent permanent neurologic damage. corticosteroids used to reduce the inflammatory damage to the brain in TBM can impair the delivery of antituberculous antibiImmune modulatory therapy in human TBM is surrounded by controversy. It is widely believed that the use of corticosteotics into the subarachnoid space. An alternative adjunctive antiinflammatory therapy for TBM is clearly needed. We thereroids soon after the start of antituberculous treatment can be life-saving, especially during clearance of bacilli [34] . Experifore evaluated the effect of thalidomide, a known TNF-a inhibitor, on antibiotic activity in the CSF and on CSF inflammation mental studies suggest that corticosteroids depress inflammatory processes and thereby reduce cerebral edema and connecand disease outcome in mycobacteria-infected rabbits. In our experimental model, thalidomide reduced TNF-a protive tissue formation, thus preventing arteritis and meningeal adhesions [35 -37] . Patient trials have also shown that dexaduction in the CSF and in the blood in a dose-dependent manner. Leukocytosis was also reduced throughout the whole pemethasone administration before the start of antibiotic treat-/ 9d46$$ju52
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